The Biostatistics component of the Administrative-Biostatistics Core will reside within the University of Pittsburgh Cancer Institute's (UPCI) Biostatistics Facility, which provides clinical and basic-science investigators in UPCI with statistical expertise in design, analysis, and reporting of cancer-related research studies. These cover basic-science studies;phase I and phase II oncology clinical trials;epidemiologic studies, including those related to cancer prevention and awareness;and investigations of behavioral and health sequelae of cancer treatment. Biostatistics will support all three research projects. We will collaborate with investigators on statistical aspects of the design of in vitro and in vivo laboratory-based studies as new data come to light, and perform both exploratory and confirmatory statistical analyses of the resulting data from key experiments. For the clinical trials that are planned in Project 1 and Project 3, we will collaborate with basic scientists and clinicians on finalizing the development of protocols that are methodologically sound, and that will pass scientific, ethical, and regulatory review. We will perform interim analyses of safety for the clinical trials, and final analyses of their data on safety, immune response, and treatment efficacy. We will work with the project investigators, UPCI Informatics, and with UPCI Clinical Research Services to ensure that the requisite laboratory and clinical-trial data are available for statistical analyses. We will collaborate with the project investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94
Guo, Z S; Bartlett, D L (2014) Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 21:261-3
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847-57
Hamilton, Ronald; Krauze, Michal; Romkes, Marjorie et al. (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:2737-46
Kohanbash, Gary; McKaveney, Kayla; Sakaki, Masashi et al. (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-*. Cancer Res 73:6413-23
Okada, Hideho; Scheurer, Michael E; Sarkar, Saumendra N et al. (2013) Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci 1284:17-23
Sampath, Padma; Li, Jun; Hou, Weizhou et al. (2013) Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 21:620-8
Yeung, Jacky T; Hamilton, Ronald L; Ohnishi, Koji et al. (2013) LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 19:1816-26
Bartlett, David L; Liu, Zuqiang; Sathaiah, Magesh et al. (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103

Showing the most recent 10 out of 37 publications